About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Cytotherapy
›
Top Articles
Cytotherapy
Transplantation
,
Oncology
,
Biology
,
Immunology
,
Genetics
,
Cell Biology
4.8
(top 12%)
Impact Factor
5.1
(top 12%)
extended IF
93
(top 4%)
H-Index
2.2K
authors
2.6K
papers
73K
citations
3.9K
citing journals
35.4K
citing authors
Most Cited Articles of Cytotherapy
Title
Year
Citations
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
2006
11K
Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement
2005
1.4K
Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT)
2013
1.1K
Adipose-derived adult stem cells: isolation, characterization, and differentiation potential
2003
834
Yield of human adipose-derived adult stem cells from liposuction aspirates
2004
534
Immunomodulatory effects of fetal and adult mesenchymal stem cells
2003
404
Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure
2006
338
The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?
2013
312
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
2011
301
Treatment of patients with advanced cancer with the natural killer cell line NK-92
2013
289
Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal
2013
285
Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration
2009
283
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
2008
279
International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials
2016
278
The current landscape of the mesenchymal stromal cell secretome: A new paradigm for cell-free regeneration
2016
277
Defining the risks of mesenchymal stromal cell therapy
2010
249
Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing
2012
237
Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature
2019
220
Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta
2004
218
Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints
2013
217
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
2009
212
Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture
2005
209
Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components
2012
207
Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia
2014
205
Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy
2011
204
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.